Back to results
US 2015/0079108 A1Published application
Kinases as targets for anti-diabetic therapy
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
InventorsMathias Falcenberg, Axel Ullrich
Life of this patent
Estimating the term…
Abstract
The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
Claims6
A method for treatment of diabetes comprising:
- administering to a subject in need thereof a therapeutically effective amount of at least one inhibitor for:
- a) inhibition of [GRK5] G protein-coupled receptor kinase 5, or
- b) inactivation, degradation, downregulation, intercalation of at least one nucleic acid encoding [GRK5] G protein-coupled receptor kinase 5, wherein the at least one inhibitor is a small interfering RNA molecule or a precursor thereof, a microRNA molecule or a precursor thereof, a small molecule, an antisense oligonucleotide or an antibody.
Dependencies are inferred from the claim text.